'Avx is working with Shanghai TargetDrug Company to target this replication process (virus) and identify inhibitors. The introduction of this discovery program into Avexa's program is the result of the successful nomination of lead compounds from both the HIV-integrase and the antibiotic programs for progression into extended studies. Hepatitis C affects 180 million people globally and with only half of all HCV patients benefiting from current therapy, unmet medical needs are very high. Datamonitor estimates the HCV market will grow to $4.4b in 2010 and $8.8b in 2015.'
AVX Price at posting:
12.0¢ Sentiment: Hold Disclosure: Held
